US Bancorp’s Xeris Biopharma Holdings XERS Stock Holding History

US Bancorp’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-444	Closed	-$1K	–	4255
2022 Q1	$1K	Buy	+444	New	+$1.08K	﹤0.01%	4015

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

US Bancorp's XERS Position: Q2 2022 in Review

US Bancorp sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 444 shares — an estimated $1K sold.

US Bancorp first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

US Bancorp reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
US Bancorp sold 444 Xeris Biopharma Holdings shares in Q2 2022, an estimated $1K.
US Bancorp first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
US Bancorp's Xeris Biopharma Holdings position peaked at $1K in Q1 2022.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.